Burk Holdings’s Charles River Laboratories CRL Stock Holding History

Burk Holdings’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.04K	Hold	9	–	–	﹤0.01%	501
2026 Q1	$1.55K	Buy	+9	New	+$1.67K	﹤0.01%	549

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Burk Holdings's CRL Position: Q2 2026 in Review

Burk Holdings held its Charles River Laboratories (CRL) position steady in Q2 2026 at 9 shares worth $2.04K. The position accounts for ﹤0.01% of the portfolio, ranked #501.

Burk Holdings first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Burk Holdings held 9 shares of Charles River Laboratories worth $2.04K as of Q2 2026.
Burk Holdings left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Burk Holdings's portfolio in Q2 2026, its #501 holding.
Burk Holdings first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Burk Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.